Search results for "SAR"

showing 10 items of 6699 documents

Activation of a murine autoreactive B cell by immunization with human recombinant autoantigen La/SS-B: Characterization of the autoepitope

1995

Immunization of Balb/c mice with a homogeneously purified recombinant human La/SS-B protein resulted in activation of an autoreactive B cell secreting a novel monoclonal anti-La antibody termed La4B6. La4B6 reacted with La protein from a variety of sources including human, bovine, rat and mouse. ATP blocked the binding of La4B6 to recombinant La protein. The human epitope was identified as consisting of the amino acid sequence SKGRRFKGKGKGN, which includes the proposed ATP-binding site of the La protein. In the human and bovine La protein, the epitope exists as a continuous amino acid sequence. In rat and mouse the epitope was found to consist of the amino acid sequence SKG interrupted by a…

medicine.drug_classRecombinant Fusion ProteinsImmunologyMolecular Sequence DataAutoimmunityBiologyMonoclonal antibodyAutoantigensPC12 CellsEpitopelaw.inventionCell LineMiceAdenosine TriphosphatelawmedicineImmunology and AllergyAnimalsHumansElméleti orvostudományokAmino Acid SequenceGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)Peptide sequencechemistry.chemical_classificationB-LymphocytesMicroscopy ConfocalLinear epitopeOrvostudományok3T3 CellsMolecular biologyAmino acidRatschemistryMicroscopy FluorescenceRibonucleoproteinsRecombinant DNAbiology.proteinCattleImmunizationAntibodyEpitope MappingGene DeletionConformational epitope
researchProduct

Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension.

1998

The stimulation of autocrine and paracrine factors such as basic fibroblast- (bFGF) and platelet-derived (PDGF) growth factors mediates many of the growth-promoting actions of angiotensin II. The aim of this study was to evaluate the effect of chronic AT1-receptor blockade on plasma endothelin-1 (ET-1) and growth factors levels, and on left ventricular mass, in essential hypertension (EH). The study population consisted of 16 patients with mild-moderate EH, and 25 normotensive controls. In the EH patients under basal conditions, and after 3 and 6 months of chronic therapy with Losartan 50 mg/day, we measured serum levels of ET-1, bFGF and PDGF, and tumor necrosis factor (TNF). At the same t…

medicine.hormoneAdultMalemedicine.medical_specialtyAngiotensin receptorAmbulatory blood pressureHeart VentriclesEssential hypertensionLosartanEndothelinsAngiotensin Receptor AntagonistsInternal medicineBlood plasmaInternal MedicineMedicineHumansGrowth SubstancesAntihypertensive Agentsbusiness.industryEndothelinsMyocardiummedicine.diseaseAngiotensin IILosartanBlood pressureEndocrinologyChronic DiseaseHypertensionFemalebusinessmedicine.drugAmerican journal of hypertension
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficien…

2020

In November 2019, the Italian Society of Endocrinology (SIE) has published a consensus statement on the tailoring of glucocorticoid replacement in adrenal insufciency [1]. A few months later, a novel severe acute respiratory syndrome coronavirus (SARS-CoV2) has been recognized as responsible for COVID-19. The outbreak has now reached pandemic level, with a high global mortality rate [2]. From February on, Italy has experienced an exponential rise in the infected which is estimated to reach 200,000 people, with an overall lethality of approximately 10% [3]. A recent Chinese series of nearly 50,000 patients with confrmed COVID-19 infection found that approximately one-out-of-fve (19%) evolve …

medicine.medical_specialty2019-20 coronavirus outbreakConsensusCoronavirus disease 2019 (COVID-19)Hormone Replacement TherapyEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralConsensuEndocrinologyGlucocorticoidmedicineAdrenal insufficiencyHumansSteroids.Hormone replacement therapyViralIntensive care medicinePandemicsAdrenal insufficiency; COVID-19; Glucocorticoids; SARS-CoV2GlucocorticoidsPandemicbusiness.industryCoronavirus InfectionCOVID-19Pneumoniamedicine.diseaseCOVID-19 Drug TreatmentItalyExpert opinionSARS-CoV2SteroidsbusinessCoronavirus InfectionsCoronavirus InfectionsAdrenal insufficiencyHuman
researchProduct

Providing pediatric well-care and sick visits in the COVID-19 pandemic era: the recommendations of the Italian pediatric society.

2020

AbstractPediatricians have observed a significant decrease in in-person child health visits during the COVID-19 pandemic. In the post lockdown period, the coronavirus trend remains positive in Italy but fears of a second wave have recently grown in Italy due to active hotbeds of contagion. The pandemic may negatively affect the care of pediatric patients and overall children welfare as it may present with severe signs and symptoms or it may complicate. The Italian Pediatric Society recommend to separate well visits from sick ones, to educate families and to promote hygienic strategies to provide an adequate pediatric assistance in case of a second pandemic wave.

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)COVID19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)media_common.quotation_subjectPneumonia ViralChild WelfareSigns and symptomsPediatricsChild healthBetacoronavirusPandemicmedicineDisease Transmission InfectiousHumansVisitChildChildrenPandemicsSocieties Medicalmedia_commonMaternal and child healthbusiness.industrySARS-CoV-2lcsh:RJ1-570COVID-19lcsh:PediatricsSettore MED/38ItalyFamily medicinePractice Guidelines as TopicCommentarybusinessCoronavirus InfectionsWelfareItalian journal of pediatrics
researchProduct

COVID-19 and diabetes management: What should be considered?

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Clinical effectivenessbusiness.industryEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cardiovascular disease COVID-19 Diabetes DPP4 GLP-1RA Hydroxychloroquine Pioglitazone SGLT-2General Medicinemedicine.diseaseEndocrinologyDiabetes managementDiabetes mellitusInternal MedicinemedicineSodium-Glucose Cotransporter 2 InhibitorIntensive care medicinebusinessPioglitazonemedicine.drugDiabetes research and clinical practice
researchProduct

Is elimination of HCV in 2030 realistic in Central Europe.

2021

According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV e…

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Hepatitis C virusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.disease_causeAntiviral Agents03 medical and health sciences0302 clinical medicineEpidemiologymedicinePrevalenceHumansHepatologybusiness.industrySARS-CoV-2virus diseasesCOVID-19Hepatitis Cmedicine.diseaseVirologyHepatitis Cdigestive system diseasesHcv eliminationEuropeRegimen030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials

2021

ABSTRACTEndothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and critically-ill patients with COVID-19. This manuscript provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterpri…

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Hospitalized patientsbusiness.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)law.inventionClinical trialRandomized controlled triallawAntithromboticmedicineIllness severityIntensive care medicinebusiness
researchProduct

Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Inclusion (disability rights)Pneumonia ViralMEDLINEArticlelaw.inventionBetacoronavirusRandomized controlled triallawHumansMedicinePregnancy Complications InfectiousIntensive care medicinePandemicsClinical Trials as TopicPregnancySARS-CoV-2business.industryPatient SelectionCOVID-19clinical trialmedicine.diseasedrug developmentClinical trialAnesthesiology and Pain MedicineDrug developmentFemalepregnancyCoronavirus Infectionsbusinessrandomised controlled trialBritish Journal of Anaesthesia
researchProduct

Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Pneumonia ViralMEDLINEBetacoronavirusRisk FactorsInternal medicinePandemicAtrial FibrillationmedicineHumansRisk factorPandemicsbiologybusiness.industrySARS-CoV-2Discussion ForumCOVID-19Atrial fibrillationmedicine.diseasebiology.organism_classificationPrognosisItalyCardiovascular DiseasesCardiology and Cardiovascular MedicinebusinessCoronavirus InfectionsCoronavirus InfectionsBetacoronavirusEuropean heart journal
researchProduct